spacer
home > pmps > winter 2018 > every drop counts
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Every Drop Counts

Drugs based on blood plasma or other biological microorganisms are – in comparison to chemical-based materials – expensive in their extraction. It is equally costly and complex to process these products to obtain a safe API. Even the smallest quantities represent high financial value. All processes, in particular filling and closing, and the upstream and downstream functions must be designed to generate the maximum output of pharmaceuticals from an existing product quantity.

The biopharmaceutical market is continually growing. These drugs might have the greatest potential to solve the medical challenges of the near future, such as multi-resistant germs and rare diseases.

To meet the special requirements of these expensive pharmaceuticals, the entire filling and packaging process has been analysed and revised. During this, waste caused by underfilling should be avoided, as should overfilling. If the overfill fluctuates within a defined tolerance, expensive product is involuntarily ‘given away’. On the other hand, if the fill volume is outside the tolerance, the container must be rejected. Many other factors in the manufacturing process have a significant impact on the maximised product yield, according to the experts at the Schwäbisch Hall company. These factors are explained in more detail later.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthias Poslovski, a graduate mechanical engineer, has been with the Optima Group since 1998. He began his career with the company as Sales Manager of the former division Inova pharma systems. From 2000 to 2002, Matthias managed the Optima division of Kugler; its expertise was in non-sterile filling and packaging technology. Today, he holds the title of Director Technical Sales at Optima Pharma. His responsibilities encompass the overall support of sales worldwide. 
spacer
Matthias Poslovski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement